Kohmann Bosshard Financial Services LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 1,071 shares of the biopharmaceutical company’s stock, valued at approximately $28,000.

Other large investors also recently made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the 4th quarter worth $26,000. Gladius Capital Management LP raised its stake in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the period. Noble Wealth Management PBC acquired a new stake in Pfizer during the 4th quarter worth $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer during the 3rd quarter worth $35,000. Finally, Joseph Group Capital Management raised its stake in Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 771 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PFE. UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Guggenheim reiterated a “buy” rating and set a $33.00 target price on shares of Pfizer in a report on Monday, February 10th. Finally, Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.21 on Tuesday. The stock has a market capitalization of $148.53 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 0.64 and a beta of 0.64. The business has a 50-day moving average of $26.34 and a 200-day moving average of $27.30. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.56%. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.